<DOC>
	<DOC>NCT02183168</DOC>
	<brief_summary>Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Active ankylosing spondylitis (pain rated &gt;= 40 mm on a VAS and increased of at least 30% after nonsteroidal antiinflammatory drugs (NSAIDs) washout)), without peripheral arthritis and inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>